SABER Study for Selected Early Stage Breast Cancer

Inclusion criteria

• Female, ≥ 50 years of age.
• Oncotype or MammaPrint diagnosis results are required prior to the start of treatment
• Histologically confirmed invasive breast cancer.
• Clinical stage T1N0M0.
• Receptor status: Estrogen-Receptor (ER)/Progesterone-Receptor (PR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative.
• Unifocal breast cancer.
• Eastern Cooperative Oncology Group (ECOG) 0, 1.
• Ability to undergo MRI.
• Women of child-bearing potential (WOCBP) must agree to use adequate contraception or agree to undergo sexual abstinence prior to study entry and for the duration of study participation. WOCBP must have a negative serum or urine pregnancy test at time of enrollment. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
• Ability to understand the investigational nature, potential risks and benefits of the research study and willingness to sign the written informed consent and HIPAA document(s).

Exclusion criteria

• Patients without histologically confirmed invasive breast cancer.
• Patients without Oncotype or MammaPrint diagnosis results at the start of treatment.
• Patients with metastatic disease.
• ECOG 2, 3, 4.
• Patients that are unable to undergo MRI.
• Prior history of radiation to the chest.
• History of collagenous disease (systemic lupus erythematosus, scleroderma, dermatomyositis).
• Any serious medical or psychiatric illness/condition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment.
• Diagnosis of another primary malignancy within the last 5 years with the exception of non-melanoma skin cancer.
• Patients unable to consent, who are pregnant or nursing, or are prisoners.